Watch CNXU. Know when insiders buy.
One email the day a filing lands. Free.
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jul 31 | — | — | — | −$7.7M | −$7.7M | — | -0.29 | −$6.8M | $41K | −$6.8M | Sep 14 |
| Q2 2026 · Apr 30 | — | — | — | −$2.4M | −$2.3M | — | -0.11 | — | — | — | Jun 15 |
| Q3 2025 · Jul 31 | — | — | — | −$1.3M | −$1.3M | — | -0.09 | −$574K | $400 | −$574K | Sep 14 |
| Q2 2025 · Apr 30 | — | — | — | −$457K | −$458K | — | -0.05 | — | — | — | Jun 15 |
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|
Every number comes from Conexeu Sciences Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.